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ABSTRACT 
Objective: The objective of this study was to measure the rate of persistence to 
antidepressants and to identify the factors influencing persistence to these medications 
in patients with diabetes.  
Methods: We conducted a retrospective study among patients with diabetes enrolled 
in a commercial health plan between 2009 – 2012. The study population includes 
patients who were at least 18 years of age and diagnosed with major depression during 
this period. The patients were eligible for acute phase treatment and continuation phase 
treatment if they were enrolled at least 90 days and 180 days after the Index 
antidepressant Prescription Start Date (IPSD) respectively. The patients were eligible 
for the study if (1) there was no history of diagnosis of major depression for at least 
120 days prior to the first episode of major depression (Index Episode Start Date-
IESD) and (2) there was no history of an antidepressant dispensing for at least 90 days 
prior to the IPSD.   
Results: The mean age of the patients in both the phases was approximately 60 years. 
A majority were prescribed SSRI (Selective Serotonin Reuptake Inhibitors) 
antidepressants in acute (71.5%) and continuation (74.9% ) treatment phases , 81.8% 
of the patients in acute phase and 72.8%  in continuation phase had monotherapy, 210 
patients  in acute phase and 112 patients in continuation phase had no follow up visits. 
Only 60.1 % and 43.5% of patients were found to be persistent to acute and 
continuation treatment phases respectively.  
Acute Phase Treatment: The odds of non-persistence were higher for patients in age 
group 18-40 compared to patients aged 40 above (OR 0.46 P=0.0036). Across the 
  
class of antidepressants patients utilizing trazadone or mirtazapine (OR=2.35 P=0.02) 
were more likely to non-persist. Patients who had 1 to 3 (OR=0.19 P<0.0001) or more 
than 3 (OR= 0.63 P<0.0001)follow up visits were found to have lower odds for non 
persistence compared to patients with no follow up visits during the treatment. Patients 
who had a combination treatment with either buproprion or tricyclic antidepressants 
(TCA) were found to be more likely to non-persist (OR 2.85 P=0.003).  
Continuation Phase Treatment: The odds of non-persistence were higher for patients in 
age group 18-40 compared to patients aged 40 above (OR 0.52 P=0.03). Patients who 
had 1 to 3 (OR 0.1 P<0.0001) or more than 3 (OR 0.13 P<0.0001)follow up visits 
were found to have lower odds for non-persistence compared to patients with no 
follow up visits during the treatment period 
Conclusion: In this population of commercially-insured patients having diabetes, 
acute phase persistence with antidepressant therapy was found to be associated with 
age, antidepressant class, type of therapy and intensity of follow up visits where as 
continuation treatment persistence was associated with age and intensity of follow up 
visits. 
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CHAPTER 1 
 
INTRODUCTION 
 
     In the United States the prevalence of diabetes is increasing with approximately 8% 
of the population or 26 million people diagnosed with this disease.
1
 It is very crucial 
for patients with diabetes to adhere to their medication to have glycemic control 
2
and 
also to decrease hospitalizations and health care costs.
3
 
       Approximately 15 million adults in the United States are affected by major 
depression which is highly recurrent.
4,5
 It is estimated that 9.5% of the adult 
population suffer from depressive illness every year.
6
 People with depression have 
negative effects such as suicidal behavior, higher health care utilization and costs, 
lower quality of life and reduction in employment productivity.
7-9
 To achieve previous 
levels of functioning and to prevent reoccurrence of depression, adherence to 
antidepressant medication is critical.
10-12
 
     The increased prevalence of depressive symptoms and major depressive disorder in 
patients with diabetes has been documented by many studies.
13
 The prevalence of 
depression in diabetic population is approximately double the prevalence of 
depression in the general population.
14
  Symptoms of depression are present in 
approximately 30% of people with diabetes 
15
and approximately 10% of people with 
diabetes have major depression.
16
 Li et al found that 45% of patients with diabetes 
have undiagnosed depression which suggests even higher rates of prevalence of both 
these conditions together.
17
 Comorbid depression in diabetes patients is severe and 
 2 
 
persistent.
18
 Lustman et al found that in patients with comorbid major depression and 
diabetes the rates of relapse of depression were as high as 79% over 5 year period with 
a mean of 4 or more episodes during that period.
19,20
 
  Patients with comorbid diabetes and depression are more likely to be non-adherent to 
the medication regimen
21
 and also show poor diabetes management compared to 
patients without depression.
22
 Depression is associated with higher hemoglobin A1c 
(HbA1c) levels,
23
 poor adherence to diet, exercise and medication regimen in patients 
with diabetes.
24-27
 It is also associated with greater symptom burden,
28
 functional 
impairment,
25,26
  micro and macro vascular complications,
29
 higher health care costs
26
 
and mortality.
29
 For example  a study conducted by Ciechanowski et al on patients 
enrolled in a health maintenance organization  having diabetes  with higher severity of 
depression symptoms, subjects had worse physical and mental functioning,  higher 
non-adherence to oral hypoglycemic regimens (15% vs. 7%) 51% higher primary , 
75% higher ambulatory  and 86% higher total health care costs compared to patients 
with low severe symptoms of depression.
26
 These facts suggest the importance of 
effective treatment of depression in patients with diabetes to improve the health 
outcomes.  
     When compared to non-depressed patients, depressed patients are three times more 
likely to be non-adherent to treatment recommendations. 
30
In one study conducted 
amongst primary care patients about one-third discontinued their antidepressant 
therapy within one month of the initiation of the treatment and about half discontinued 
within three months.
31
 Lowest rates of adherence were found in patients with diabetes 
(67.5%) compared to patients with other chronic conditions (pulmonary-68.8% and 
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cardiovascular diseases-76.6%) in a study conducted by DaMatteo et al.
32
 These facts 
together suggest even lower adherence rates in patients with comorbid depression and 
diabetes. A major barrier to improving care in people with comorbid depression and 
diabetes is their poor adherence to the treatment.
30
 
The objective of this study was to measure the rate of persistence to antidepressants 
and to identify the factors influencing persistence to these medications in patients with 
diabetes.  
We hypothesized that one of the covariates among the patient demographic (age, 
gender, health plan) or clinical factors (Comorbidity score, insulin utilization, 
hospitalization, psychotherapy, type of antidepressant, class of antidepressant, type of 
therapy) or physician factors (follow up visits) better predicts the persistence to 
antidepressant therapy. 
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CHAPTER 2 
 
METHODOLOGY 
 
Study Design: We conducted a retrospective cohort study using a sample of 
commercially insured patients. The data set consisted of health care claims occurring 
from 2009 through 2012. All the members of this dataset have at least one 
International Classification of Disease-9 (ICD-9) code for diabetes during this period. 
The enrollment file has demographic information describing age, gender, health plan, 
enrolment start date and end date. The prescription file contains information 
describing National Drug Codes (NDC), drug names, dates of prescription dispensing , 
days of supply of the medication provided, national provider ID, copayment and 
prescription cost. The professional file includes information describing medical 
service use including diagnosis and procedure codes and payment amounts. The 
facility file has information describing ICD codes, Current Procedural Terminology 
(CPT) codes, revenue codes, copayment, cost paid to the facility, admit dates and 
discharge dates. 
Study population: The study population includes patients enrolled in the 
commercial plan who were at least 18 years of age and diagnosed with major 
depression during 2009-2012 (International Classification of Diseases codes 296.20-
296.25, 296.30-296.35, 298.0, 311). The patients were eligible for acute phase 
treatment and continuation phase treatment if they were enrolled at least 90 days and 
180 days after the Index antidepressant Prescription Start Date (IPSD) respectively. 
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The patients were eligible for the study if (1) there was no history of diagnosis of 
major depression for at least 120 days prior to the first episode of major depression 
(Index Episode Start Date-IESD) and (2) there was no history of an antidepressant 
dispensing for at least 90 days prior to the IPSD.  Since persistence with particular 
drug therapy was a variable of our interest, we excluded the patients who switched the 
drug therapy during the treatment period.  
 
  
 
                               Figure 1. Time frame for the enrollment of subjects in the study 
 
 
 
Index Prescription Start Date 
Date 
Negative Medication History                                                                    Continuous Phase Treatment 
90 Days 84Days 96 Days 
          Acute Phase Treatment 
6
 
 7 
 
Figure 2. Eligible population for acute phase treatment persistence measurement 
 
 
Patients with diagnosis for Major Depression (N=2587) 
 
Therefore N= 2663-76=2587 
Patients with Negative Diagnosis History 
(NDH) N=2247 (86.8%) 
 
Patients with Negative Medication history 
(NMH) and at least 90 day follow up after IPSD 
N=756 (29.2%) 
 
Patients with both NDH and NMH N=717 (27.7%) 
Patients with age less than 17(N=7) and 
Switching (N=23) 
 
Final Sample N=687(26.5%) 
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Figure. 3 Eligible population for continuation treatment phase persistence 
measurement 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients with diagnosis for Major Depression (N=2587) 
 
Therefore N= 2663-76=2587 
Patients with Negative Diagnosis History 
(NDH) N=2247 (86.8%) 
 
Patients with Negative Medication history 
(NMH) and at least 180 day follow up after 
IPSD N=738 (28.4%) 
 
Patients with both NDH and NMH N=650 (25.13%) 
Patients with age less than 17(N=7) and 
Switching (N=41) 
 
Final Sample N=602(23.27%) 
 9 
 
Dependent Variable: The dependent variable for the study was persistence to the 
antidepressant therapy. Effective acute phase treatment was defined as at least 84 days 
of continuous treatment with antidepressants within 114 days after the IPSD. Effective 
continuous phase treatment was defined as at least 180 days of continuous treatment 
with antidepressants within 231 days after the IPSD. The patients who meet these 
criteria were identified as persistent to therapy and who do not meet were identified as 
non-persistent to the therapy. The persistence to therapy during acute phase and 
continuous phase were evaluated in different models. 
Independent variables: Age, gender, Charlson comorbidity index, insulin utilization, 
hospitalization, psychotherapy, class and type of the antidepressant, type of 
antidepressant therapy, health plan and intensity of follow- up care were the 
independent variables examined in this study. Age was coded in categories with age 
group 18-40 and above 41. The classes of antidepressants considered were tricyclic 
antidepressants (TCA), SSRI’s (Selective Serotonin Reuptake Inhibitors), SSNRI’s 
(Selective Serotonin Norepinephrine Reuptake Inhibitors), phenyl piperazines, 
tetracyclic antidepressants and bupropion. The Charlson comorbidity index provides 
the overall measure of disease burden and predicts the mortality by weighing different 
comorbid conditions of the patient; this score was calculated for each patient for all 
the disease conditions in the time frame studied and was used for assessing the 
comorbidity of the patients in this study. The score was coded in categories with 
scores of 1 to 3 and more than 3. Follow up visits for any purpose during the treatment 
phase were counted for both the phases. The visits were coded as 0, 1-3 visits and 
more than 3 visits. 
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Statistical Analysis: Descriptive statistics for each variable were used to summarize 
the study population. Bivariate analyses were conducted to assess the association 
between the dependent variable and each independent variable. Univariate logistic 
regression was performed to select the variables with significant P-Values (0.2) for 
final model (Table 7 and Table 8 in Appendix). Interactions and colinearity were 
assessed between the independent variables. Multivariate logistic regression was 
performed to examine the multivariate associations of the independent variables with 
the dependent variable (persistence to antidepressant therapy during acute phase 
treatment and continuous phase treatment) and odds ratios were used to measure the 
association. Separate analyses were performed for the acute and continuous phases. 
The significance level was set at 0.05 and 95% Confidence Intervals were examined. 
All the statistical analyses were performed using SAS statistical software version 9.3.                                       
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CHAPTER 3 
 
FINDINGS 
 
Acute Phase Treatment Persistence 
Table 1 provides the base line demographic and clinical characteristics of the study 
population. The mean age of this population was 60.5 years and a majority of the 
patients were females (56.8%).The mean comorbid score in this study population was 
3.4. Additionally 44.69% of the patients received psychotherapy during the acute 
phase treatment. Insulin utilization was observed in 31% of these patients. Forty- four 
(6.4%) patients were hospitalized. A majority (65.2%) of them were enrolled in non-
HMO (Health Maintenance Organization) plans. Most of these patients (81.8%) had 
antidepressant monotherapy. No follow up visits were in 30.6% of patients during the 
treatment period. Generic antidepressant drugs were prescribed to 84.6% of the 
patients. A majority of the population (71.5%) were prescribed SSRI’s followed by 
SSNRI’s (8.7%). 
 
In the bivariate analysis (Table 2) age, antidepressant class, type of therapy and follow 
up visits were found to have a significant association with persistence to 
antidepressant medication during the acute phase treatment. Patients adherent during 
the acute phase were aged 41 or above (61.8%) vs. 18-40 years (47.5%), prescribed an 
SSRI antidepressant (61.7%) or SSNRI (63.3%) or bupropion (64.1%) and were on 
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monotherapy (62.6%). Higher rates of persistence were found in patients having 1-3 
(79.4%) or more than 3 follow up visits (53.9%). 
 
In the multivariate analysis (Table 3) age, class of antidepressant, type of therapy and 
follow up visits were found to be significantly associated with persistence to acute 
phase treatment after adjusting for other variables. The odds of non-persistence were 
higher for patients in age group 18-40 compared to patients aged 40 above (OR 0.46 
P=0.0036). Across the class of antidepressants patients utilizing other (trazadone and 
mirtazapine) antidepressants (OR=2.35 P=0.02) were more likely to not persist 
compared to patients utilizing SSRI’s, whereas no difference was observed in the rates 
of persistence in patients utilizing SSNRI’s, TCA, bupropion and SSRI’s. Patients 
who had 1 to 3 (OR=0.19 P<0.0001) or more than 3 (OR= 0.63 P<0.0001)follow up 
visits were found to have lower odds for non-persistence compared to patients with no 
follow up visits during the treatment. Patients who had a combination treatment with 
either buproprion or TCA were found to be more likely to non-persist (OR 2.85 
P=0.003) where as there was no difference in rates of persistence in patients who had a 
combination treatment either with trazadone or mirtazapine. 
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Continuation Phase Treatment Persistence 
Table 4 shows the baseline demographic and clinical characteristics of the population 
in the continuous phase. The mean age of the study population during this treatment 
was 60.4. The proportion of females was higher (56.8%) than males. The mean 
comorbid score for this population was 3.4. Approximately 43% of patients received 
psychotherapy during this period. Insulin utilization was observed in 30.7% of the 
patients. Fourty patients (6.6%) were hospitalized during this period. Similar to the 
population in acute phase treatment a majority of the patients (65.8%) in this treatment 
phase were also enrolled in a non-HMO health plan. A higher percentage of people 
had monotherapy (72.8%). No follow up visits were observed in 18.6% of patients 
during the treatment period. Most of the patients were prescribed (83.6%) generic 
antidepressants similar to the patients in acute phase treatment. A majority of them 
were prescribed SSRI’s (74.9%) followed by SSNRI’s (9.0%).  
 
In the bivariate analysis (Table 5) age and follow up visits were found to have a 
significant association with persistence to antidepressant medication during the 
continuous phase treatment. Patients adherent during the continuous phase were aged 
41 or above (45.1%) vs. 18-40 years (30.3%). Higher rates of persistence were found 
in patients having 1-3 (56.2%) or more than 3 (48.9%) follow up visits compared to 
patients with no follow up visits (11.6%). 
In the multivariate analysis (Table 6) age and follow up visits were found to be 
significantly associated with persistence to continuous phase treatment after adjusting 
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for other variables. The odds of non-persistence were higher for patients in age group 
18-40 compared to patients aged 40 above (OR=0.52 P=0.03). Patients who had 1 to 3 
(OR=0.1 P<0.0001) or more than 3 (OR=0.13 P<0.0001)follow up visits were found 
to have lower odds for non-persistence compared to patients with no follow up visits 
during the treatment period. 
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Table 1. Demographic and clinical characteristics of a population of commercially 
insured patients: Acute phase persistence with antidepressant medications (N=687) 
 
Variable N % 
Age(Mean 60.5,SD16.7) 
18-40 80 11.7 
41-64 352 51.3 
65 and above 255 37.0 
Gender 
  Male 297 43.2 
Female 390 56.8 
Comorbidity Score(Mean 3.4,SD 2.7) 
1 214 31.0 
2 106 15.5 
3 or more 367 53.5 
Insulin  
Yes 213 31 
No 474 69 
Hospitalization 
Yes 44 6.4 
No 643 93.6 
Psychotherapy 
Yes 307 44.7 
No 380 55.3 
Type of Antidepressant 
Generic 581 84.6 
Brand 81 11.8 
Brand and Generic 25 3.6 
Antidepressant Class 
SSRI 491 71.5 
SSNRI 60 8.7 
Tricyclic Antidepressants 39 5.7 
Bupropion 39 5.7 
Others 58 8.4 
Type of therapy 
Monotherapy 562 81.8 
Combination with 
trazadone/mirtazapine 85 12.4 
Combination with Others 40 5.8 
Health Plan 
HMO 239 34.8 
Non-HMO 448 65.2 
Follow up Visits 
0 210 30.6 
1 to 3 247 35.9 
more than 3 230 33.5 
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Table2. Bivariate Analysis: Factors associated with persistence to acute phase 
antidepressant treatment in commercially insured patients 
Variable Persistent Non-Persistent Chi-Sq P-value 
    
 
413(60.1%) 274(39.9%) 
 Age 0.014 
18-40 38 (47.5%) 42(52.5%) 
 41 and above 375(61.8%) 232(38.2%) 
 Gender 0.07 
Male  190(64%) 107(36%) 
 Female  223(57.2%) 167(42.8%) 
 Comorbidity Score 0.59 
1 to 3 266(60.9%) 171(39.1%) 
 4 and above 147(58.8%) 103(41.2%) 
 Insulin 0.4 
Yes 123(57.7%) 90(42.3%) 
 No 290(61.2%) 184(38.8%) 
  Hospitalization 0.42 
Yes 29(65.9%) 15(34.1%) 
 No 384(59.7%) 259(40.3%) 
 Psychotherapy 0.14 
Yes 194(63.2%) 113(36.8%) 
 No 219(57.6%) 161(42.4%) 
 Type of Antidepressant 0.91 
Generic  351(60.4%) 230(39.6%) 
 Brand 47(58%) 34(42%) 
 Generic and Brand 15(60%) 10(40%) 
 Antidepressant Class 0.03 
SSRI 306(61.7%) 185(37.7%) 
 SSNRI 38(63.3%) 22(36.7%) 
 Tricyclic Antidepressants 17(43.6%) 22(56.4%) 
 Bupropion 25(64.1%) 14(35.9%) 
 Others 27(46.6%) 31(53.4%) 
 Type Of Therapy 0.01 
Monotherapy 352(62.6%) 210(37.4%) 
 Combination with Trazadone/ Mirtazapine 44(51.8%) 41(48.2%) 
 Combination with Others 17(42.5%) 23(57.5%) 
 Health Plan 0.55 
HMO 140(58.6%) 99(41.4%) 
 Non-HMO 273(60.9%) 175(39.1%) 
 Follow up Visits <0.0001 
0 93(44.3%) 117(55.7%) 
 1 to 3 196(79.4%) 51(20.6%) 
 More than 3 124(53.9%) 106(46.1%) 
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Table 3. Estimated odds ratios and 95% confidence intervals of antidepressant 
treatment persistence during acute phase treatment 
Variable  Odds Ratio 95% CI P-Value 
Age 0.0036 
18-40 1 
  
41 and above 0.46 0.27-0.78 
 
Gender 0.069 
Male  0.73 0.52-1.03 
 
Female 1 
  
Comorbidity Score 0.6 
1 to 3 1 
  
4 and above 1.09 0.76-1.56 
 
Antidepressant Class 
  
0.02 
SSRI 1 
  
SSNRI 0.94 0.52-1.71 
 
TCA 1.62 0.78-3.31 
 
Bupropion 0.83 0.4-1.7 
 
Others 2.35 1.29-4.29 
 
Follow up visits 
  
<0.0001 
0 1 
  
1 to 3 0.19 0.12-0.29 
 
more than 3 0.63 0.42-0.93 
 
Type of therapy 
  
0.003 
Monotherapy 1 
  Combination with Trazadone/ 
Mirtazapine 1.74 1.05-2.88 
 
Combination with Others 2.85 1.41-5.78 
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Table 4. Demographic and clinical characteristics of a population of commercially 
insured patients: Continuation phase treatment persistence with antidepressant 
medications 
Variable N % 
Age(Mean60.4,SD16.2) 
18-40 66 11.0 
41-64 319 52.9 
65 and above 217 36.1 
Gender 
Male 260 43.2 
Female 342 56.8 
 Comorbidity Score(Mean3.4,SD2.6) 
1 186 30.9 
2 94 15.6 
3 or more 322 53.5 
Insulin  
Yes 185 30.7 
No 417 69.3 
Hospitalization 
Yes 40 6.6 
No 562 93.4 
Psychotherapy 
Yes 257 42.7 
No 345 57.3 
Type of Antidepressant 
Generic 503 83.6 
Brand 59 9.8 
Brand and Generic 40 6.6 
Class of Antidepressant 
SSRI 451 74.9 
SSNRI 54 9.0 
Tricyclic Antidepressants 35 5.8 
Bupropion 29 4.8 
Others 33 5.5 
Type of therapy 
Monotherapy 438 72.8 
Combination with Trazadone/Mirtazapine 109 18.1 
Combination with other 55 9.1 
Health Plan 
HMO 206 34.2 
Non-HMO 396 65.8 
Follow up Visits 
0 112 18.6 
1 to 3 128 21.3 
more than 3 362 60.1 
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Table 5. Bivariate Analysis: Factors associated with persistence to continuation phase 
antidepressant treatment in commercially insured patients 
Variable Persistent Non-Persistent Chi-Sq P-value 
 
262(43.5%) 340(56.5%) 
 Age 0.02 
18-40 20(30.3%) 46(69.7%) 
 41 and above 242(45.1%) 294(54.9%) 
 Gender 0.8 
Male  115(44.2%) 145(55.8%) 
 Female  147(43%) 195(57%) 
 Comorbidity Score 0.6 
0 to 3 163(42.7%) 219(57.3%) 
 4 and above 99(45%) 121(55%) 
 Insulin 0.8 
Yes 79(42.7%) 106(57.3%) 
 No 183(43.9%) 234(56.1%) 
 Hospitalization 0.1 
Yes 13(32.5%) 27(67.5%) 
 No 249(44.3%) 313(55.7%) 
 Psychotherapy 0.3 
Yes 118(45.9%) 139(54.1%) 
 No 144(41.7%) 201(58.3%) 
 Type Of Antidepressant 0.6 
Generic  218(43.3%) 285(56.7%) 
 Brand 24(40.7%) 35(59.3%) 
 Generic and Brand 20(50%) 20(50%) 
 Antidepressant Class 0.3 
SSRI 199(44.1%) 252(55.9%) 
 SSNRI 28(51.9%) 26(48.1%) 
 Tricyclic Antidepressants 11(31.4%) 24(68.6%) 
 Bupropion 13(44.8%) 16(55.2%) 
 Others 11(33.3%) 22(66.7%) 
 Type of Therapy 0.1 
Monotherapy 201(45.9%) 237(54.1%) 
 Combination with 
Trazadone/Mirtazapine 38(34.7%) 71(65.1%) 
 Combination with Other 23(41.8%) 32(58.2%) 
 Health Plan 0.7 
HMO 92(35.1%) 170(64.9%) 
 Non-HMO 114(33.5%) 226(66.5%) 
 Follow up visits <0.0001 
0 13(11.6%) 99(88.4%) 
 1 to 3 72(56.2%) 56(43.8%) 
 More than 3 177(48.9%) 185(51.1%) 
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Table 6. Estimated odds ratios and 95% confidence intervals of antidepressant 
treatment persistence during continuation phase treatment 
Variable  Odds Ratio 95% CI P-Value 
Age 0.03 
18-40 1 
  
41 and above 0.52 0.29-0.94 
 
Gender 0.86 
Male  0.99 0.70-1.41 
 
Female 1 
  
Comorbidity Score 0.99 
0-3 1 
  
4 and above 0.97 0.67-1.38 
 
Follow Up Visits <0.0001 
0 1 
  
1 to 3 0.1 0.05-0.19 
 
more than 3 0.13 0.07-0.25 
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                                                  CHAPTER 4 
 
DISCUSSIONS, LIMITATIONS AND CONCLUSION 
 
       In this study we assessed the antidepressant treatment persistence rates and the 
factors associated with persistence to these medications in the acute phase and 
continuation phase treatment periods. Results of our study indicate that only 60.12 % 
and 43.52 % of patients were persistent to acute and continuation phase respectively. 
Persistence was significantly influenced by age, class of antidepressant, type of 
therapy and intensity of follow up visits during the acute phase treatment where as 
only age and intensity of follow up visits had an effect on persistence to the therapy 
during continuation phase.  
 
As expected a majority of the patients were prescribed SSRI’s as they are most 
frequently utilized for depression and the preferable antidepressants for diabetic 
patients as they might show beneficial effects on glycemic control.
33-35
 
 
Older age was found to be associated with persistence to the antidepressant medication 
in both acute and continuous phases. This finding was consistent with the previous 
research
36-38
 that older people were more likely to be adherent to the therapy compared 
to younger people. For example, in a study conducted by Akincigil et al on privately 
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insured patients, patients who were age 50 or above were found to be 2.48 times more 
likely to be adherent compared to patients with 18-25 years.  This might be due to the 
possibility that older people are more experienced in managing their medication 
regimen to various disease conditions which makes it easier for them to manage 
antidepressant medication as well. Another possible explanation might be they are 
more worried about mortality compared to younger population. 
 
The class of antidepressant utilized was significantly associated with persistence 
during the acute phase but had no influence during the continuation phase. This might 
be due to the side effects or adverse events due to these drugs during the initial 
treatment. It could be assumed that patients who had no side effects with these drugs 
in acute phase treatment persisted with their medication in continuation phase and 
therefore the class of drug had no influence on persistence in this phase .Patients who 
were prescribed SSRI’s were more likely to be persistent to acute phase treatment 
which was a similar result in previous studies
39
. There was no difference in the rates of 
persistence to the therapy among SSRI’s SSNRI’s, TCA and bupropion. Patients 
receiving other antidepressants (trazadone and mirtazapine) were less likely to persist 
with effective acute phase treatment. One reason for this might be that these drugs 
were prescribed for insomnia while the primary treatment was psychotherapy. Another 
reason might be due to the adverse effects of these drugs such as weight gain, 
dizziness etc. 
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It was also found that patients who had a combination therapy with SSRI/SSNRI and 
bupropion or TCA were less likely to persist. This might be due to the side effects due 
to the combination of these drugs such as remarkably lower blood pressure with 
combination of TCA and SSRI.
40
 However a meta-analysis by Seetal et al found that 
combination of SSRI/SSNRI with bupropion was well tolerated.
41
 Another reason 
might be these patients have severe depression resulting in less motivation to take the 
medicines.  
 
We also found that patients who have either 1 to 3 or more than 3 follow up visits are 
more likely to be persistent to the therapy compared to patients with no follow up 
visits. It was found in the previous research that patients with 3 or more follow up 
visits were more likely to persist.
36,37,42
 One reason for this might be that the physician 
could possibly educate the patient about the importance of taking the medications 
regularly. Another reason might be these patients are more cautious about their health 
and therefore have frequent follow up visits with the physician and take their 
medications regularly.  
 
Our study has several limitations. (1)Reliance on claims data, which might have 
coding errors due to insufficient information provided by the physician about ICD 
codes, CPT codes etc. Also the deliberate miscoding of major depression with other 
diagnosis codes by physicians
43
 further increases the chances of coding errors in 
identifying patients with major depression. (2)If the patient receives prescription or 
care outside the health plan network or if the patient receives samples by the provider 
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in the office it will not be shown in the claims data. (3)We assumed that patients who 
had prescription for the antidepressants as persistent which might not actually reflect 
the actual utilization of these drugs by the patients.(4) In the HEDIS (Healthcare 
Effectiveness Data and Information Set)   algorithm patients who switched the 
therapies are also included in the calculation of rates of persistence but in this study 
since we  excluded them so the rates of persistence in this study might be 
underestimated if the patients who switched their therapy were persistent.(5)The 
generalization of these results might be limited to commercial health plans and 
patients with diabetes.  
 
In this population of commercially insured patients having diabetes, acute phase 
persistence with antidepressant therapy was found to be associated with age, 
antidepressant class, type of therapy and intensity of follow up visits where as 
continuation treatment persistence was associated with age and intensity of follow up 
visits.
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APPENDICES 
Table 7. Results of univariate logistic regression analysis for acute phase treatment 
persistence 
Variable Persistent Non Persistent Odds Ratio 95% CI P-Value 
 Age 0.015 
18-40 38(5.53%) 42(6.11%) 1 
  41 and above 375(54.59%) 232(33.77%) 0.56 (0.35-0.89) 
 Gender 0.07 
Female  223(32.46%) 167(24.31%) 1 
  Male  190(27.66%) 107(15.57%) 0.75 0.55-1.03 
 Comorbidity Score 0.59 
3-Jan 266(38.72%) 171(24.89%) 1 
  4 or more 147(21.4%) 103(14.99%) 1.09 (0.8-1.5) 
 Insulin 0.39 
Yes 123(17.9%) 90(13.1%) 1.15 0.83-1.6 
 No 290(42.2%) 184(26.78%) 1 
  Hospitalization 0.4 
Yes 29(4.22%) 15(2.18%) 0.77 0.4-1.46 
 No 384(55.9%) 259(4.22%) 1 
  Psychotherapy 0.14 
Yes 194(28.24%) 113(16.45%) 0.79 0.58-1.08 
 No 219(31.88%) 161(23.44%) 1 
  Tpe of Antidepressant 0.9 
Generic 351(51.09%) 230(33.48%) 1 
  Brand 47(6.84%) 34(4.95%) 1.1 0.69-1.77 
 Generic and Brand 15(2.18%) 10(1.46%) 1.02 0.45-2.4 
 Antidepressant Class 0.04 
SSRI 306(44.54%) 185(26.93%) 1 
  SNRI 38(5.53%) 22(3.2%) 0.96 0.55-1.67 
 TCA 17(2.47%) 22(3.2%) 2.14 1.1-4.14 
 Bupropion 25(3.64%) 14(2.04%) 0.93 0.47-1.83 
 Others 27(3.93%) 31(4.51%) 1.9 1.01-3.3 
 Type of Therapy 0.012 
Monotherapy 352(51.24%) 210(30.57%) 1 
  Combination with Trazadone 
or Mirtazapine 44(6.40%) 41(5.97%) 1.56 0.9-2.5 
 Combination with Other 17(2.47%) 23(3.35%) 2.27 1.18-4.34 
 Health Plan 
 HMO 140(20.38%) 99(14.41%) 1 
  Non-HMO 273(39.74%) 175(25.47%) 0.9 0.66-1.25 
 Follow up Visits 
 
<0.001 
0 93(13.54%) 117(17.03%) 1 
  1 to 3 196(28.53%) 51(7.42%) 0.21 0.14-0.31 
 more than 3 124(18.05%) 106(15.43%) 0.68 0.47-0.99 
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Table 8. Result of univariate logistic regression analysis for continuation phase 
treatment persistence. 
Variable Persistent Non-Persistent 
Odds 
Ratio 95% CI P-Value 
Age 0.02 
18-40 20(3.32%) 46(7.64%) 1 
  41 and above 242(40.20%) 294(48.84%) 0.53 0.3-0.9 
 Gender 0.76 
Female  147(24.42%) 195(32.39%) 1 
  Male  115(19.10%) 145(24.09%) 0.95 0.69-1.32 
 Comorbidity Score 0.58 
0-3 163(27.08%) 219(36.38%) 1 
  4 or more 99(16.45%) 121(20.10%) 0.91 0.65-1.27 
  Insulin 0.78 
Yes 79(13.12%) 106(17.61%) 1.05 0.74-1.49 
 No 183(30.4%) 234(38.87%) 1 
  Hospitalization 0.15 
Yes 13(2.16%) 27(4.49%) 1.65 0.84-3.27 
 No 249(41.36%) 313(51.99%) 1 
  Psychotherapy 0.3 
Yes 118(19.6%) 139(23.09%) 0.84 0.6-1.17 
 No 144(23.92%) 201(33.39%) 1 
  Type of Antidepressant 0.6 
Generic 218(36.21%) 285(47.34%) 1 
  Brand 24(3.99%) 35(5.81%) 1.12 0.65-1.93 
 Generic and Brand 20(3.32%) 20(3.32%) 0.77 0.4-1.46 
 Antidepressant Class 0.29 
SSRI 199(33.06%) 252(41.86%) 1 
  SSNRI 28(4.65%) 26(4.32%) 0.73 0.42-1.29 
 TCA 11(1.83%) 24(3.99%) 1.72 0.82-3.6 
 Bupropion 13(2.16%) 16(2.66%) 0.97 0.46-2.07 
 Others 11(1.83%) 22(3.65%) 1.58 0.75-3.33 
 Type of Therapy 0.1 
Monotherapy 201(33.39%) 237(39.37%) 1 
  Combination with 
Trazadone/Mirtazapine 38(6.13%) 71(11.79%) 1.59 1.02-2.45 
 Combination with other 23(3.82%) 32(5.32%) 1.18 0.67-2.08 
 Health Plan 0.68 
HMO 92(15.28%) 114(18.94%) 1 
  Non-HMO 170(28.24%) 226(37.54%) 1.07 0.76-1.5 
 Follow Up Visits <0.0001 
0 13(2.16%) 99(16.45%) 1 
  1 to 3 72(11.96%) 56(9.3%) 0.1 0.05-0.2 
 more than 3 177(29.40%) 185(30.73%) 0.14 0.07-0.3 
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Model Building 
Acute Phase Treatment Persistence: 
Univariate logistic regression was performed between the dependent variable and each 
independent variable and interactions were assessed between the significant variables. 
Age, gender, psychotherapy, antidepressant class, type of therapy and follow up visits 
were found to be significant at a P-value significance of 0.2 for the acute phase 
treatment (Table 7).Psychotherapy and gender became non significant in the 
multivariate analysis.  The model with interaction and the model with no interactions 
were compared to select the final model. 
Model 1:  No-interaction model 
 
Model 2: Model with interactions 
 
The AIC (Akaike Information Criterion) of model 1 and model 2 were 847.6 and 
847.5 respectively. The models were  
 
compared using log likelihood ratio test. 
 
Likelihood Ratio Test. 
H0: Model 1 
 
Ha: Model 2  
 
LR Test:  
                          2 Log L model1 – 2 Log L model 2 = 827.5-823.64=3.9 
 
                           Degrees of Freedom = 12-10=2    P-Value= 0.14 
 
The LR test suggests that the model with no interactions terms included explains 
better. Also the co linearity diagnostics indicate co linearity in the model with 
interactions as the variance inflation factors for all the variables (except age) were 
greater than 6. Thus the model with no interactions was selected as the final model. 
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The variance inflation factors in the model with no interaction terms were close to 1 
and the condition index was less than 30 confirming no colinearity. The model fit was 
assessed using Hosmer-Lemeshow Goodness of fit (GOF) and ROC curves. The GOF 
P-value (0.9) was greater than 0.05 and AUC (0.7) was greater than 0.5indicating an 
adequate model fit 
Table 9. Goodness of Fit test for acute phase model 
Hosmer- Lemeshow Goodness-of-Fit Test 
  
   
Chi-Square DF Pr > ChiSq 
2.9328 8 0.9385 
 
Figure 4. Receiver Operating Characteristic (ROC) Curve for acute phase model 
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Continuation Treatment Phase Persistence  
Age, follow up visits, hospitalization and type of therapy were found to be significant 
in the univaraite logistic regression for continuation phase treatment. No interactions 
between these variables were found to be significant.  When all variables that were 
significant in the univariate logistic regression were included in the model 
hospitalization and type of therapy were non-significant. Therefore, the final model 
included the clinically important variables such as gender and comorbity score along 
with significant variables age and follow up visits. This model was then assesses for 
co linearity. The variance inflation factors were near to 1 and the condition index was 
less than 30 confirming no co linearity in this model. The model fit was assessed using 
Hosmer-Lemeshow Goodness of Fit and ROC curves. The GOF P-value (0.6) was 
greater than 0.05 and AUC (0.65) was greater than 0.5indicating an adequate model fit 
 
Table 10. Goodness of Fit for continuation phase model 
Hosmer and Lemeshow Goodness-of-Fit 
  
Test 
  
Chi-Square DF Pr > ChiSq 
4.7911 7 0.6854 
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Figure 5. ROC Curve for continuation phase model 
 
 
DV and IV Coding 
 
Dependent Variable  
Persistence to antidepressant medication: Yes (1) No (0) 
Independent Variables 
1. Age : 18-40 (1)  40 Above (2) 
2. Gender : Female (1) Male (2) 
3. Comorbdity Score 
0-3 (1) 
3 or more (2) 
4. Psychotherapy : Yes (1) No (0) 
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5. Insulin : Yes (1) No (0) 
6. Antidepressant Class 
SSRI (1) 
SSNRI (2) 
TCA (3) 
Bupropion (4) 
Trazadone and Mirtazapine (5) 
7. Type of Antidepressant  
Generic (1) 
Brand (2) 
Brand and Generic (3) 
8. Type of Antidepressant therapy 
Monotherapy (0) 
Combination (1) 
9. Hospitalization: Yes (1) No (0) 
10. Health Plan: HMO (1) Non-HMO (2) 
11. Follow up visits 
0 (1) 
1 to 3 (2) 
More than 3 (3) 
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